Spatially distinct and simultaneous resistance mechanisms, namely, EGFR L718V mutation and SCLC transformation, contributed to osimertinib resistance. The detection of RB1 2.4 kb small deletion in RB1 gene highlights the importance of deep genomic profiling. Multi-site biopsy and molecular diagnostics are necessary to guide treatment decisions in EGFR-TKI-resistant NSCLC.

15 days ago

Journal

TP53 (Tumor protein P53) • RB1 (RB Transcriptional Corepressor 1)

TP53 mutation • EGFR mutation • EGFR L858R • EGFR expression • RB1 deletion

Tagrisso (osimertinib) • Gilotrif (afatinib)

16d

Establishment and characterization of a novel cell line ICH-BCPALL-3 from B cell precursor acute lymphoblastic leukemia with TCF3::HLF. (PubMed, Hum Cell)

The cytotoxicity assay indicated that the cell line is sensitive to Aurora Kinase B inhibitor, but not to BCL2 inhibitor. This cell line is the first TCF3::HLF-positive BCP-ALL model without the t(17;19) translocation, facilitating research into leukemogenesis and the development of novel treatments for patients with poor prognosis associated with TCF3::HLF-positive BCP-ALL.

16 days ago

Preclinical • Journal • IO biomarker

KRAS (KRAS proto-oncogene GTPase) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • PAX5 (Paired Box 5) • TCF3 (Transcription Factor 3) • NCOR1 (Nuclear Receptor Corepressor 1) • AURKB (Aurora Kinase B) • VPREB1 (V-Set Pre-B Cell Surrogate Light Chain 1) • ARID5B (AT-Rich Interaction Domain 5B)

CDKN2A deletion • RB1 deletion

22d

A Case of Rare Adipocytic Tumor of the Tongue: Lipoblastoma-Like Tumor With RB1 Gene Deletion. (PubMed, Cureus)

This case highlights the diagnostic challenges of differentiating LLTs from spindle cell lipomas (SCLs), particularly in the context of pRB deficiency and RB1 deletion. This case exemplifies the molecular heterogeneity of neoplasms with lipoblastoma-like features.

22 days ago

Journal

BCL2 (B-cell CLL/lymphoma 2) • RB1 (RB Transcriptional Corepressor 1) • MDM2 (E3 ubiquitin protein ligase) • CDK4 (Cyclin-dependent kinase 4) • CD34 (CD34 molecule) • DDIT3 (DNA-damage-inducible transcript 3) • PLAG1 (PLAG1 Zinc Finger)

RB1 deletion

30d

Potential Loss of Imprinting of Tumor Suppressor Gene RB1 in Triple Negative Breast Cancer. (PubMed, Breast Cancer Res)

RB1 exhibits potential LOI in TNBCs, laying the groundwork for more precise subtyping and treatment of TNBC patients.

30 days ago

Journal

RB1 (RB Transcriptional Corepressor 1) • CDK4 (Cyclin-dependent kinase 4)

RB1 deletion

A rare case of cellular angiofibroma with sarcomatous transformation occurred in the popliteal fossa. (PubMed, Discov Oncol)

This report highlights a rare and extraordinary case of CAS identified in the popliteal fossa. Through NGS, we had identified concurrent deletions of the RB1 and TP53 genes. Although the prognosis of this case was slightly worse than that reported in the literature, it provides additional evidence for expanding the known anatomical range of CAF.

1 month ago

Journal

TP53 (Tumor protein P53) • RB1 (RB Transcriptional Corepressor 1) • MDM2 (E3 ubiquitin protein ligase) • CDK4 (Cyclin-dependent kinase 4)

RB1 deletion

2ms

Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Report. (PubMed, Iran J Pathol)

Extensive testing, including a bone marrow (BM) smear and biopsy, revealed numerous abnormal or blastic cells. Furthermore, flow cytometric analysis of the BM confirmed the presence of plasmacytoid dendritic cell-neoplastic precursor cells exhibiting CD4+ and CD56+ characteristics.

2 months ago

Journal

TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • CD123 (Interleukin 3 Receptor Subunit Alpha) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • IL3RA (Interleukin 3 Receptor Subunit Alpha) • CDKN1B (Cyclin dependent kinase inhibitor 1B)

RB1 deletion

2ms

Uterine leiomyosarcoma progression: A study of serial recurrences. (PubMed, Gynecol Oncol)

Primary uLMS and subsequent recurrences display genomic intra-individual concordance, with sustained driver cancer gene alterations over time. Chromosomal instability was higher in recurrent tumors.

2 months ago

Journal • BRCA Biomarker

ER (Estrogen receptor) • TP53 (Tumor protein P53) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1) • ATRX (ATRX Chromatin Remodeler)

TP53 mutation • PTEN mutation • RB1 deletion • ESR1 mutation

2ms

Precision medicine in prostate cancer: individualized treatment through radiomics, genomics, and biomarkers. (PubMed, Cancer Imaging)

Integrating these technologies into personalized treatment plans and the broader framework of precision medicine allows for an in-depth exploration of the relationship between specific biomarkers and disease pathogenesis. This review summarizes the current research on radiomics, genomics, and biomarkers in PCa, and discusses their future potential and applications in advancing individualized patient care.

2 months ago

Review • Journal • BRCA Biomarker

TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1) • ERG (ETS Transcription Factor ERG) • TMPRSS2 (Transmembrane serine protease 2) • PCA3 (Prostate cancer associated 3)

TP53 mutation • PTEN mutation • RB1 deletion

4ms

Phase II study of the efficacy and safety of palbociclib in patients with recurrent ovarian cancer. (PubMed, Int J Gynecol Cancer)

Palbociclib demonstrated only modest clinical activity in unselected patients with ovarian cancer. However, cyclin-dependent kinases 4/6 inhibition showed promising clinical activity in low-grade serous ovarian cancer, warranting further study in this subtype. Further biomarker analyses may facilitate patient selection in high-grade serous ovarian cancer.

4 months ago

P2 data • Journal

CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • CCNE1 (Cyclin E1) • MUC16 (Mucin 16, Cell Surface Associated)

HR positive • CDKN2A deletion • RB1 deletion

Ibrance (palbociclib)

4ms

ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)

P2, N=61, Active, not recruiting, Rahul Aggarwal | Recruiting --> Active, not recruiting

4 months ago

Enrollment closed

PD-L1 (Programmed death ligand 1) • RB1 (RB Transcriptional Corepressor 1)

RB1 deletion

Keytruda (pembrolizumab) • Xtandi (enzalutamide) • ZEN-3694

6ms

Defining CDK12 as a tumor suppressor and therapeutic target in mouse models of tubo-ovarian high-grade serous carcinoma. (PubMed, Proc Natl Acad Sci U S A)

Our results define CDK12 as a key tumor suppressor in tubo-ovarian HGSC and highlight CDK13 targeting as a promising therapeutic approach in CDK12-inactive disease. Additionally, we have established valuable in vivo resources to facilitate further investigation and drug development in this challenging malignancy.

6 months ago

Preclinical • Journal

TP53 (Tumor protein P53) • RB1 (RB Transcriptional Corepressor 1) • NF1 (Neurofibromin 1) • CDK12 (Cyclin dependent kinase 12) • CDK13 (Cyclin Dependent Kinase 13)

RB1 deletion

7ms

RB1 and p53 are diagnostic markers for treatment-related neuroendocrine prostate cancer: a clinical and pathological analysis of 23 cases. (PubMed, Am J Clin Exp Urol)

Notably, a histologically confirmed t-NEPC case with neuroendocrine marker negativity exhibited RB1/p53 co-alterations, molecularly aligning with most neuroendocrine-positive cases. These findings substantiate that combined RB1/p53 aberrations serve as robust diagnostic indicators for t-NEPC, particularly in tumors exhibiting small cell carcinoma morphology without neuroendocrine marker expression.

7 months ago

Journal

TP53 (Tumor protein P53) • AR (Androgen receptor) • RB1 (RB Transcriptional Corepressor 1) • CEACAM5 (CEA Cell Adhesion Molecule 5)

TP53 mutation • RB1 deletion